Torrent Pharma gets USFDA observations for Dahej plant

Torrent Pharma announced that the audit at Dahej plant in Gujarat was carried out by US Food and Drug Administration (USFDA) in March 2019.

New Delhi: Drug firm Torrent Pharmaceuticals said the US health regulator has issued certain observations after the audit at its Dahej plant.

Torrent Pharma announced that the audit at Dahej plant in Gujarat was carried out by US Food and Drug Administration (USFDA) in March 2019.

"The company has received certain observations which are procedural in nature and the company is confident of addressing them satisfactorily," the company said in a BSE filing.

Also Read: USFDA issues 4 observations for Torrent Pharmaceuticals Indrad plant

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group. Based in the Indian city of Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

The company is active in the therapeutic areas of Cardiovascular (CV), central nervous system (CNS), gastro-intestinal, diabetology, anti-infective and pain management segments.

It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments.

Also Read: Indian Pharma companies biggest violators of USFDA integrity norms